Repetitive transcranial magnetic stimulation is a non-invasive neuromodulation method that utilizes electromagnetic pulses to modulate neural activity in specific brain regions. Traditionally, rTMS has been most notably applied to treat conditions including major depressive disorder and obsessive-compulsive disorder. Its FDA approval for smoking cessation marks a significant extension into addiction therapy. However, challenges remain, such as the modest effectiveness across diverse patient populations and side effects like localized discomfort and headaches.

The research team, led by Dr. Xingbao Li, an associate professor within MUSC’s Department of Psychiatry and Behavioral Sciences, set out to enhance the precision and efficacy of rTMS by identifying neural markers predictive of individual treatment response. Using functional magnetic resonance imaging (fMRI), they captured resting-state and task-induced brain activity patterns from smokers exposed to cues such as images and videos associated with smoking behavior. This advanced neuroimaging technique measures changes in blood flow, serving as an indirect proxy for neuronal activity.

Central to their findings is the salience network, a major brain system responsible for filtering and prioritizing stimuli based on their behavioral relevance. While prior research predominantly focused on the reward network—governing motivation and pleasure—in nicotine addiction, this study reveals the salience network as a critical mechanistic bridge between rTMS modulation and successful smoking cessation. This insight challenges prevailing assumptions and opens new avenues for therapeutic targeting.

To analyze the high-dimensional and complex fMRI data, the team employed machine learning algorithms capable of detecting subtle and nonlinear patterns predictive of treatment outcomes. This approach overcomes conventional limitations by allowing computers to autonomously identify dysfunctional neural connectivity profiles without explicit programming rules. The result is a multivariate biomarker framework that can individualize rTMS treatment parameters.

Building upon an earlier MUSC clinical trial involving 42 adult smokers, where participants underwent either real or sham rTMS treatments paired with exposure to smoking-related stimuli, the current study leveraged retrospective imaging data. In that trial, real rTMS over the left dorsolateral prefrontal cortex was associated with significant reductions in daily cigarette consumption, cravings, and higher abstinence rates compared to the control group.

With the integration of fMRI and machine learning, the present study demonstrates that the connectivity strength within the salience network robustly predicts who benefits most from rTMS interventions. This predictive capability heralds a shift from uniform treatment protocols toward precision neuromodulation, where therapeutic strategies are tailored based on an individual’s neurobiological profile.

The implications of this research extend beyond nicotine addiction. The multimodal biomarker pipeline established here could be adapted for other substance use disorders, potentially transforming how neuropsychiatric conditions are managed. This personalized approach may reduce side effects by avoiding ineffective treatments and expedite recovery by focusing on neural circuits that critically govern addictive behavior.

Dr. Li emphasizes that the study paves the way for larger-scale investigations to validate and refine these findings. The success of such interdisciplinary efforts underscores the synergistic power of combining advanced neuroimaging, machine learning, and clinical neuroscience to tackle complex brain disorders.

Funding for this research was provided by the National Institutes of Health, and the team reported no conflicts of interest. Contributors include Kevin Caulfield, Ph.D., Andrew Chen, Ph.D., Christopher McMahan, Ph.D., Karen Hartwell, M.D., Kathleen Brady, M.D., Ph.D., and Mark George, M.D., all bringing expertise that spans psychiatry, neuroscience, and bioengineering.

By moving beyond static stimulation targets and embracing the heterogeneity of brain network dysfunctions in smokers, MUSC researchers exemplify how modern technology can catalyze the evolution of neurotherapeutic modalities. This study exemplifies a paradigm shift toward data-driven, individually optimized interventions, offering renewed hope to millions struggling with tobacco dependence worldwide.

Subject of Research: Neural Predictors of rTMS Efficacy in Smoking Cessation using Machine Learning and fMRI
Article Title: Salience Network Connectivity Predicts Response to Repetitive Transcranial Magnetic Stimulation in Smoking Cessation: A Preliminary Machine Learning Study
News Publication Date: 15-Sep-2025
Web References: http://dx.doi.org/10.1177/21580014251376722
References: Li, X., Caulfield, K., Chen, A., McMahan, C., Hartwell, K., Brady, K., George, M. (2025). Brain Connectivity.
Image Credits: Image courtesy of the MUSC research team
Keywords: Substance related disorders, Behavioral neuroscience

At the biochemical level, tobacco smoke delivers a complex cocktail of over 7,000 chemical substances, among which approximately 70 are recognized carcinogens. These toxic agents orchestrate a devastating cascade of cellular damage, leading to myriad cancers—most prominently lung, mouth, throat, and bladder cancers—as well as chronic respiratory and cardiovascular diseases. The pathophysiology of tobacco-induced harm is multifaceted, involving persistent oxidative stress, inflammation, and direct genotoxicity, thus compounding morbidity and mortality risks associated with continued smoking. Understanding these mechanisms underscores the urgency of effective cessation interventions and substantiates the strong clinical impetus for proactive management.

Epidemiological data from 2022 indicate that about 11% of the Canadian population aged 15 and over are active smokers, with the vast majority engaging in daily use. Socio-demographic studies reveal disproportionate prevalence within certain subpopulations—such as individuals who are single, separated, divorced, or widowed; members of the LGBTQ+ community; Indigenous peoples including First Nations, Inuit, and Métis; individuals experiencing mental health disorders or substance use issues; and workers in occupations not requiring specialized education. These disparities reflect underlying social determinants of health, highlighting the need for culturally sensitive, accessible cessation resources.

Clinicians are urged to integrate systematic assessment of smoking status into routine patient evaluations as a fundamental aspect of preventive healthcare. This involves not only identifying smoking habits but also fostering patient engagement through empathetic communication and shared decision-making frameworks. The guideline emphasizes personalized treatment planning, acknowledging both the heterogeneity of tobacco dependence and patient readiness to quit. Such an approach can optimize adherence and outcomes by aligning cessation strategies with individual motivations and barriers.

Behavioural interventions constitute a cornerstone of smoking cessation, encompassing a diverse array of modalities. Primary care advice delivered by clinicians has demonstrated efficacy, especially when combined with subsequent support. Trained cessation counsellors provide individualized or group sessions via in-person or telephonic formats, furnishing tailored coping strategies and relapse prevention techniques. Digital solutions, including text messaging interventions, offer scalable, low-cost support that can augment traditional behavioral therapies. Self-help materials, another accessible resource, empower users to engage proactively in their quit journey with evidence-based guidance.

Pharmacotherapy remains critical in addressing the neurochemical underpinnings of nicotine addiction. Nicotine replacement therapies (NRT) — including patches, gums, lozenges, inhalers, and sprays — supply nicotine in controlled doses, mitigating withdrawal symptoms while eliminating exposure to toxic tobacco combustion products. Other first-line agents such as varenicline and bupropion function through modulation of nicotinic acetylcholine receptors and neurotransmitter pathways, reducing cravings and reward-associated reinforcement. Notably, the guideline incorporates cytisine, a plant-derived alkaloid classified as a natural health product, which acts as a partial nicotinic receptor agonist and shows promise as a cost-effective cessation aid.

Emerging evidence supports the synergistic benefit of combining behavioural and pharmacotherapy interventions, maximizing quit rates through multimodal approaches. Such strategic integration addresses both the psychological and physiological dimensions of addiction, enabling more robust and sustained abstinence. Conversely, the guideline strongly advises against the use of unproven and potentially misleading therapies including acupuncture, hypnosis, laser therapy, electric current stimulation, ear acupressure, St. John’s Wort, and S-adenosyl-L-methionine (SAMe), based on insufficient evidence of effectiveness and potential risks.

A nuanced consideration is warranted regarding the role of e-cigarettes, or electronic nicotine delivery systems, in cessation efforts. While some data suggest they may facilitate quitting for individuals who have unsuccessfully tried other methods, widespread recommendation remains conditional due to unresolved concerns. The absence of standardized product formulations, lack of regulatory approval, and insufficient long-term safety data underscore their ambiguous risk-benefit profile. Moreover, e-cigarettes continue to perpetuate nicotine dependence and may not adequately address behavioral aspects of smoking addiction. Consequently, the guideline advises reserving e-cigarette use for select patients expressing a strong preference or demonstrating resistance to conventional therapies.

The guideline development process was rigorous and collaborative, incorporating the perspectives of people who smoke or have recently quit, thus aligning recommendations with patient-centered outcomes such as successful abstinence and enhanced quality of life. Expertise was further enhanced through consultation with physician-scientists specialized in tobacco addiction treatment and hospital-based cessation program implementation. Input from organizational stakeholders ensured that the guideline reflects practical realities and facilitates broad adoption within clinical practice.

Public health implications of this guideline are profound. Tobacco remains the single greatest cause of preventable mortality in Canada, responsible for substantial healthcare costs and diminished life expectancy. By furnishing clinicians with a flexible, evidence-based toolkit, this initiative aims to close gaps in cessation support and elevate quit rates, thereby mitigating tobacco-related disease burden. The guideline’s deployment through infographics, patient–clinician discussion tools, podcasts, and other knowledge translation resources enhances reach and usability.

In editorial commentary accompanying the guideline’s release, Dr. Matthew Stanbrook, deputy editor of the Canadian Medical Association Journal, endorses the prudence of a cautious stance on e-cigarettes. He emphasizes the necessity of prioritizing established, scientifically validated interventions to maximize the public health benefit while avoiding inadvertent harms associated with uncertain modalities. His reflections underscore a broader commitment to evidence integrity in formulating tobacco control strategies.

Despite significant progress over the past 50 years in reducing smoking prevalence, tens of thousands of Canadians continue to suffer the consequences of tobacco dependence. This new guideline represents a critical advancement in aligning clinical practice with current scientific understanding and patient needs. It empowers healthcare providers to forge more effective partnerships with their patients, enabling tangible progress toward quitting—a life-changing intervention poised to save countless lives.

The complexity of tobacco addiction demands multifaceted, adaptable solutions that balance pharmacologic efficacy with behavioural support and patient autonomy. By integrating cutting-edge evidence with practical implementation frameworks, this guideline sets a new standard in preventive medicine. Harnessing these tools, clinicians can significantly sway the trajectory of tobacco-related morbidity and mortality in Canada, contributing to a healthier, smoke-free future.

Subject of Research: People
Article Title: Recommendations on interventions for tobacco smoking cessation in adults in Canada
News Publication Date: 25-Aug-2025
Web References: https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241584
References: https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241584
Keywords: Substance related disorders, Cancer, Esophageal cancer, Lung cancer, Respiratory disorders, Cardiovascular disorders, Tobacco